Review of draft FDA adaptive design guidance

Journal of Biopharmaceutical Statistics

Volumn 20, Issue 6, 2010, Pages 1132-1142

  Cook, Thomas ^a   Demets, David L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adaptive design; Efficiency; FDA guidance; Information

Indexed keywords

ADAPTIVE DESIGN; CLINICAL RESEARCH; CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HUMAN; METHODOLOGY; PRIORITY JOURNAL; REVIEW; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC ERROR;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; GUIDELINES AS TOPIC; HUMANS; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 78249274248     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.514455     Document Type: Review

References (20)

1. Chang, M. N., Gould, A. L., Snapinn, S. M. (1995). P-values for group sequential testing. Biometrika 82:650-654.
2. Chen, Y. H. J., DeMets, D. L., Lan, K. K. G. (2004). Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 23 (7):1023-1038.
3. Cook, T. D. (2002). P-value adjustment in sequential clinical trials. Biometrics 58 (4):1005-1011.
4. Cook, T. D., DeMets, D. L., eds. (2008). Introduction to Statistical Methods for Clinical Trials. New York: Chapman & Hall/CRC Press.
5. Cui, L., Hung, H. M. J., Wang, S.-J. (1999). Modification of sample size in group sequential clinical trials. Biometrics 55:853-857.
6. Dargie, H. J., and the CAPRICORN Steering Committee. (2000). Design and methodology of the CAPRICORN trial-A randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure 2 (3):325-332.
7. DeMets, D. L., Pocock, S. J., Julian, D. G. (1999). The agonizing negative trend in monitoring of clinical trials. Lancet 354:1983-1988.
8. Dupont, W. D. (1983). Sequential stopping rules and sequentially adjusted p values: does one require the other? Controlled Clinical Trials 4:3-10.
9. Emerson, S. S. (2006). Issues in the use of adaptive clinical trial designs. Statistics in Medicine 25 (19):3270-3296.
10. Fisher, L. D. (1998). Self-designing clinical trials. Statistics in Medicine 17:1551-1562.
11. Friedman, L. M., Furberg, C., DeMets, D. L. (1998). Fundamentals of Clinical Trials. New York: Springer-Verlag.
12. Jennison, C., Turnbull, B. W. (2006). Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 25 (6):917-932.
13. Lan, K. K. G., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659-663.
14. Lan, K. K. G., Trost, D. C. (1997). Estimation of parameters and sample size re-estimation. In: ASA Proceedings of the Biopharmaceutical Section. Alexandria, VA: American Statistical Association, pp. 48-51.
15. O'Brien, P., Fleming, T. (1979). A multiple testing procedure for clinical trials. Biometrics 35:549-556.
16. O'Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
17. Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324.
18. Proschan, M. A., Lan, K. K. G., Wittes, J. T. (2006). Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer.
19. Storer, B. (1989). Design and analysis of phase I clinical trials. Biometrics 45:925-937.
20. Tsiatis, A. A., Mehta, C. (2003). On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 90 (2):367-378.